The landscape of pharmacological treatment of advanced HER2-positive breast cancer is rapidly evolving, and the potential collocation of a treatment with capecitabine + lapatinib will depend on new drugs becoming available. The gene discussed is ERBB2; the disease is breast carcinoma.